Phase 3 Study of Nitazoxanide Compared to Standard Treatment for Adults with COVID-19

What this Trial Is About

Researchers are evaluating the use of Nitazoxanide for treating COVID-19, a viral infection caused by the severe acute respiratory syndrome coronavirus 2. This study aims to assess the clinical effectiveness of Nitazoxanide compared to the standard treatment protocol. The trial is conducted by Tanta University and is a Phase 3 randomized study without masking. Participants are assigned to one of two groups one receiving Nitazoxanide alongside the standard treatment, and the other receiving only the standard treatment. The study explores the potential benefits of Nitazoxanide, which has shown clinical efficacy, alongside other drugs like ivermectin and azithromycin in previous research. During the study, researchers monitor patients over six months, focusing on the number of patients achieving virological cure. Participants will undergo regular assessments to track their response to treatment. The study does not include blinding, and no placebo is used. Safety and efficacy are evaluated throughout the trial period, which began in May 2020 and is expected to end by December 2030.

Novel Regimens in COVID-19 Treatment